

(80124)

Medical Benefit		Effective Date: 04/01/13	Next Review Date: 01/20
Preauthorization	Yes	Review Dates: 04/07, 05/08, 01/10, 01/11, 01/12, 01/13, 01/14, 01/15, 01/16, 01/17, 01/18, 01/19	

Preauthorization is required and must be obtained through Case Management.

The following protocol contains medical necessity criteria that apply for this service. The criteria are also applicable to services provided in the local Medicare Advantage operating area for those members, unless separate Medicare Advantage criteria are indicated. If the criteria are not met, reimbursement will be denied and the patient cannot be billed. Please note that payment for covered services is subject to eligibility and the limitations noted in the patient's contract at the time the services are rendered.

Populations	Interventions	Comparators	Outcomes
Individuals: • With adult soft tissue sarcomas	Interventions of interest are: • Autologous hematopoietic cell transplantation	Comparators of interest are: • Standard of care	Relevant outcomes include: • Overall survival • Disease-specific survival • Treatment-related mortality • Treatment-related morbidity
Individuals: • With small cell lung cancer	Interventions of interest are: • Autologous hematopoietic cell transplantation	Comparators of interest are: • Standard of care	Relevant outcomes include: • Overall survival • Disease-specific survival • Treatment-related mortality • Treatment-related morbidity
Individuals: • With renal cell carcinoma	Interventions of interest are: • Allogeneic hematopoietic cell transplantation	Comparators of interest are: • Standard of care	Relevant outcomes include: • Overall survival • Disease-specific survival • Treatment-related mortality • Treatment-related morbidity
Individuals: • With colorectal cancer	Interventions of interest are: • Allogeneic hematopoietic cell transplantation	Comparators of interest are: • Standard of care	Relevant outcomes include: • Overall survival • Disease-specific survival • Treatment-related mortality • Treatment-related morbidity
Individuals: • With pancreatic cancer	Interventions of interest are: • Allogeneic hematopoietic cell transplantation	Comparators of interest are: • Standard of care	Relevant outcomes include: • Overall survival • Disease-specific survival • Treatment-related mortality • Treatment-related morbidity
Individuals: • With nasopharyngeal cancer	Interventions of interest are: • Allogeneic hematopoietic cell transplantation	Comparators of interest are: • Standard of care	Relevant outcomes include: • Overall survival • Disease-specific survival • Treatment-related mortality • Treatment-related morbidity

DESCRIPTION

Hematopoietic cell transplantation (HCT) is an established treatment for certain hematologic malignancies and has been investigated for a variety of adult solid tumors. Interest continues in exploring nonmyeloablative allogeneic HCT (allo-HCT) for a graft-versus-tumor effect of donor-derived T cells in metastatic solid tumors.

SUMMARY OF EVIDENCE

AUTOLOGOUS HCT

For individuals who have adult soft tissue sarcomas who receive autologous HCT, the evidence includes two TEC Assessments, a randomized controlled trial (RCT), and a number of phase 2 single-arm studies, some of which have been summarized in a systematic review. Relevant outcomes are overall survival (OS), disease-specific survival, and treatment-related mortality and morbidity. The 1995 and 1999 TEC Assessments, focusing on autologous HCT as primary and salvage therapy for a variety of solid tumors, found that the available evidence did not permit conclusions about the effect of HCT on patient survival. Although a small phase 2 randomized controlled trials reported longer survival for patients treated with autologous HCT than with standard chemotherapy, this trial did not show a survival benefit with HCT. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have small cell lung cancer who receive autologous HCT, the evidence includes two TEC Assessments, several RCTs, and systematic reviews of these studies. The relevant outcomes are OS, disease-specific survival, and treatment-related mortality and morbidity. The 1995 and 1999 TEC Assessments, focusing on autologous HCT as primary and salvage therapy for a variety of solid tumors, found that the available evidence did not permit conclusions about the effect of HCT on patient survival. Studies published since the TEC Assessments have not reported increased OS for patients with small cell lung cancer treated with autologous HCT. The evidence is insufficient to determine the effects of the technology on health outcomes.

ALLO-HCT

For individuals who have renal cell carcinoma, colorectal cancer, pancreatic cancer, or nasopharyngeal cancer who receive allo-HCT, the evidence includes a TEC Assessment and small single-arm series. The relevant outcomes are OS, disease-specific survival, treatment-related mortality and morbidity. The 1995 and 1999 TEC Assessments, focusing on allo-HCT as primary and salvage therapy for a variety of solid tumors, found that the available evidence did not permit conclusions about the effect of allo-HCT on patient survival. Since the publication of the TEC Assessments, the evidence for allo-HCT to treat renal cell carcinoma, colorectal cancer, pancreatic cancer, and nasopharyngeal cancer has been limited to small case series. The evidence is insufficient to determine the effects of the technology on health outcomes.

POLICY

Autologous or allogeneic hematopoietic cell transplant is considered **investigational** for the following malignancies in adults:

- Lung cancer, any histology
- Colon cancer
- Rectal cancer
- Pancreatic cancer
- Stomach cancer
- Esophageal cancer
- Gall bladder cancer
- Cancer of the bile duct
- Renal cell cancer
- Cervical cancer
- Uterine cancer
- Cancer of the fallopian tubes
- Prostate cancer
- Nasopharyngeal cancer
- Paranasal sinus cancer

- Neuroendocrine tumors
- Soft tissue sarcomas
- Thyroid tumors
- Tumors of the thymus
- Tumors of unknown primary origin
- Malignant melanoma

MEDICARE ADVANTAGE

If a transplant is needed, we arrange to have the Medicare–approved transplant center review and decide whether the patient is an appropriate candidate for the transplant.

BACKGROUND

HEMATOPOIETIC CELL TRANSPLANTATION

HCT is a procedure in which hematopoietic stem cells are infused to restore bone marrow function in cancer patients who receive bone-marrow-toxic doses of cytotoxic drugs with or without whole body radiotherapy. Hematopoietic stem cells may be obtained from the transplant recipient (autologous HCT) or from a donor (allogeneic HCT [allo-HCT]). They can be harvested from bone marrow, peripheral blood, or from umbilical cord blood shortly after delivery of neonates. Although cord blood is an allogeneic source, the stem cells in it are antigenically “naive” and thus are associated with a lower incidence of rejection or graft-versus-host disease (GVHD). Cord blood is discussed in detail in the Placental and Umbilical Cord Blood as a Source of Stem Cells Protocol.

Immunologic compatibility between infused hematopoietic stem cells and the recipient is not an issue in autologous HCT. However, immunologic compatibility between donor and patient is critical for achieving a good outcome of allo-HCT. Compatibility is established by typing of human leukocyte antigens (HLAs) using cellular, serologic, or molecular techniques. HLA refers to the tissue type expressed at the HLA-A, -B, and -DR (antigen-D related) loci on each arm of chromosome 6. Depending on the disease being treated, an acceptable donor will match the patient at all or most of the HLA loci (with the exception of umbilical cord blood).

Conditioning for HCT

Conventional Conditioning

The conventional (“classical”) practice of allo-HCT involves administration of cytotoxic agents (e.g., cyclophosphamide, busulfan) with or without total body irradiation at doses sufficient to destroy endogenous hematopoietic capability in the recipient. The beneficial treatment effect in this procedure is a result of a combination of initial eradication of malignant cells and subsequent graft-versus-malignancy (GVM) effect mediated by non-self-immunologic effector cells that develop after engraftment of allogeneic stem cells within the patient’s bone marrow space. While the slower GVM effect is considered to be the potentially curative component, it may be overwhelmed by extant disease without the use of pretransplant conditioning. However, intense conditioning regimens are limited to patients who are sufficiently fit medically to tolerate substantial adverse events that include pre-engraftment opportunistic infections secondary to loss of endogenous bone marrow function and organ damage and failure caused by the cytotoxic drugs. Furthermore, in any allo-HCT, immunosuppressant drugs are required to minimize graft rejection and GVHD, which also increases susceptibility to opportunistic infections. The immune reactivity between donor T cells and malignant cells that is responsible for the GVM effect also leads to acute and chronic GVHD.

The success of autologous HCT is predicated on the ability of cytotoxic chemotherapy with or without radiation to eradicate cancerous cells from the blood and bone marrow. This permits subsequent engraftment and

repopulation of bone marrow space with presumably normal hematopoietic stem cells obtained from the patient before undergoing bone marrow ablation. As a consequence, autologous HCT is typically performed as consolidation therapy when the patient's disease is in complete remission. Patients who undergo autologous HCT are susceptible to chemotherapy-related toxicities and opportunistic infections before engraftment, but not GVHD.

Reduced-Intensity Conditioning for Allo-HCT

Reduced-intensity conditioning (RIC) refers to the pretransplant use of lower doses or less intense regimens of cytotoxic drugs or radiation than are used in conventional full-dose myeloablative conditioning treatments. The goal of RIC is to reduce disease burden but also to minimize as much as possible associated treatment-related morbidity and nonrelapse mortality in the period during which the beneficial GVM effect of allogeneic transplantation develops. Although the definition of RIC remains arbitrary, with numerous versions employed, all seek to balance the competing effects of nonrelapse mortality and relapse due to residual disease. RIC regimens can be viewed as a continuum in effects, from nearly totally myeloablative, to minimally myeloablative with lymphoablation, with intensity tailored to specific diseases and patient condition. Patients who undergo RIC with allo-HCT initially demonstrate donor cell engraftment and bone marrow mixed chimerism. Most will subsequently convert to full-donor chimerism, which may be supplemented with donor lymphocyte infusions to eradicate residual malignant cells. For this protocol, RIC will refer to all conditioning regimens intended to be nonmyeloablative, as opposed to fully myeloablative (conventional) regimens.

HCT IN SOLID TUMORS IN ADULTS

HCT is an established treatment for certain hematologic malignancies. Its use in solid tumors is less well established, although it has been investigated for a variety of solid tumors. With the advent of nonmyeloablative allogeneic transplant, interest has shifted to exploring the generation of alloreactivity to metastatic solid tumors via a graft-versus-tumor effect of donor-derived T cells.¹

HCT as a treatment for ovarian cancer, germ cell tumors, ependymoma or malignant glioma is addressed separately (Hematopoietic Cell Transplantation for Epithelial Ovarian Cancer Protocol, Hematopoietic Cell Transplantation in the Treatment of Germ Cell Tumors Protocol, and Hematopoietic Cell Transplantation for Central Nervous System Embryonal Tumors and Ependymoma Protocol, respectively). HCT as a treatment for breast cancer is not addressed. This protocol collectively addresses other solid tumors of adults for which HCT has been investigated, including lung cancer, malignant melanoma, tumors of the gastrointestinal tract (affecting the colon, rectum, pancreas, stomach, esophagus, gallbladder, or bile duct), male and female genitourinary systems (e.g., renal cell carcinoma, prostate cancer, cervical cancer, uterine cancer, fallopian tube cancer), tumors of the head and neck, soft tissue sarcoma, thyroid tumors, tumors of the thymus, and tumors of unknown primary origin.

REGULATORY STATUS

The U.S. Food and Drug Administration regulates human cells and tissues intended for implantation, transplantation, or infusion through the Center for Biologics Evaluation and Research, under Code of Federal Regulation, title 21, parts 1270 and 1271. Hematopoietic stem cells are included in these regulations.

RELATED PROTOCOLS

Hematopoietic Cell Transplantation for Central Nervous System Embryonal Tumors and Ependymoma

Hematopoietic Cell Transplantation for Epithelial Ovarian Cancer

Hematopoietic Cell Transplantation for Solid Tumors of Childhood

Hematopoietic Cell Transplantation in the Treatment of Germ Cell Tumors
Placental and Umbilical Cord Blood as a Source of Stem Cells

Services that are the subject of a clinical trial do not meet our Technology Assessment Protocol criteria and are considered investigational. *For explanation of experimental and investigational, please refer to the Technology Assessment Protocol.*

It is expected that only appropriate and medically necessary services will be rendered. We reserve the right to conduct prepayment and postpayment reviews to assess the medical appropriateness of the above-referenced procedures. **Some of this protocol may not pertain to the patients you provide care to, as it may relate to products that are not available in your geographic area.**

REFERENCES

We are not responsible for the continuing viability of web site addresses that may be listed in any references below.

1. Carnevale-Schianca F, Ricchiardi A, Capaldi A, et al. Allogeneic hemopoietic stem cell transplantation in solid tumors. *Transplant Proc.* Jul-Aug 2005;37(6):2664-2666. PMID 16182778
2. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). High-Dose Chemotherapy with Autologous Stem-Cell Support for Miscellaneous Solid Tumors In Adults. TEC Assessments. 1995;10:Tab 4.
3. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Salvage High-Dose Chemotherapy with Allogeneic Stem Cell Support for Relapse Following High-Dose Chemotherapy with Autologous Stem Cell Support for Non-lymphoid Solid Tumors. TEC Assessments. 1999;14:Tab 11.
4. Pedrazzoli P, Ledermann JA, Lotz JP, et al. High dose chemotherapy with autologous hematopoietic stem cell support for solid tumors other than breast cancer in adults. *Ann Oncol.* Oct 2006;17(10):1479-1488. PMID 16547069
5. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: soft tissue sarcoma. Version 1.2018. http://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf. Accessed December 12, 2017.
6. Kasper B, Dietrich S, Mechttersheimer G, et al. Large institutional experience with dose-intensive chemotherapy and stem cell support in the management of sarcoma patients. *Oncology.* Mar 2007;73(1-2):58-64. PMID 18334832
7. Schlemmer M, Wendtner CM, Falk M, et al. Efficacy of consolidation high-dose chemotherapy with ifosfamide, carboplatin and etoposide (HD-ICE) followed by autologous peripheral blood stem cell rescue in chemosensitive patients with metastatic soft tissue sarcomas. *Oncology.* Mar 2006;71(1-2):32-39. PMID 17344669
8. Peinemann F, Enk H, Smith LA. Autologous hematopoietic stem cell transplantation following high-dose chemotherapy for nonrhabdomyosarcoma soft tissue sarcomas. *Cochrane Database Syst Rev.* Apr 13 2017; 4:CD008216. PMID 28407197
9. Bui-Nguyen B, Ray-Coquard I, Chevreau C, et al. High-dose chemotherapy consolidation for chemosensitive advanced soft tissue sarcoma patients: an open-label, randomized controlled trial. *Ann Oncol.* Mar 2012; 23(3):777-784. PMID 21652583
10. Peinemann F, Labeit AM. Autologous haematopoietic stem cell transplantation following high-dose chemotherapy for non-rhabdomyosarcoma soft tissue sarcomas: a Cochrane systematic review. *BMJ Open.* Jul 29 2014;4(7):e005033. PMID 25079925

11. Kasper B, Scharrenbroich I, Schmitt T, et al. Consolidation with high-dose chemotherapy and stem cell support for responding patients with metastatic soft tissue sarcomas: prospective, single-institutional phase II study. *Bone Marrow Transplant*. Jul 2010;45(7):1234-1238. PMID 19935728
12. Hartmann JT, Horger M, Kluba T, et al. A non-comparative phase II study of dose intensive chemotherapy with doxorubicin and ifosfamide followed by high dose ICE consolidation with PBSCT in non-resectable, high grade, adult type soft tissue sarcomas. *Invest New Drugs*. Dec 2013;31(6):1592-1601. PMID 24091981
13. Tsujimura H, Miyaki T, Yamada S, et al. Successful treatment of histiocytic sarcoma with induction chemotherapy consisting of dose-escalated CHOP plus etoposide and upfront consolidation auto-transplantation. *Int J Hematol*. Nov 2014;100(5):507-510. PMID 25062797
14. Lorigan P, Woll PJ, O'Brien ME, et al. Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer. *J Natl Cancer Inst*. May 4 2005;97(9):666-674. PMID 15870437
15. Crivellari G, Monfardini S, Stragliotto S, et al. Increasing chemotherapy in small-cell lung cancer: from dose intensity and density to megadoses. *Oncologist*. Jan 2007;12(1):79-89. PMID 17227903
16. Jiang J, Shi HZ, Deng JM, et al. Efficacy of intensified chemotherapy with hematopoietic progenitors in small-cell lung cancer: A meta-analysis of the published literature. *Lung Cancer*. Aug 2009;65(2):214-218. PMID 19118919
17. Nishimura M, Nasu K, Ohta H, et al. High dose chemotherapy for refractory urothelial carcinoma supported by peripheral blood stem cell transplantation. *Cancer*. Nov 1 1999;86(9):1827-1831. PMID 10547557
18. Airoidi M, De Crescenzo A, Pedani F, et al. Feasibility and long-term results of autologous PBSC transplantation in recurrent undifferentiated nasopharyngeal carcinoma. *Head Neck*. Sep 2001;23(9):799-803. PMID 11505492
19. Lee JA, Choi SY, Kang HJ, et al. Treatment outcome of osteosarcoma after bilateral retinoblastoma: a retrospective study of eight cases. *Br J Ophthalmol*. Oct 2014;98(10):1355-1359. PMID 24795337
20. Imanguli MM, Childs RW. Hematopoietic stem cell transplantation for solid tumors. *Update Cancer Ther*. 2006;1(3):343-352.
21. Demirer T, Barkholt L, Blaise D, et al. Transplantation of allogeneic hematopoietic stem cells: an emerging treatment modality for solid tumors. *Nat Clin Pract Oncol*. May 2008;5(5):256-267. PMID 18398414
22. Childs R, Chernoff A, Contentin N, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. *N Engl J Med*. Sep 14 2000; 343(11):750-758. PMID 10984562
23. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: kidney cancer. Version 2.2018. http://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf. Accessed December 12, 2017.
24. Bregni M, Bernardi M, Servida P, et al. Long-term follow-up of metastatic renal cancer patients undergoing reduced-intensity allografting. *Bone Marrow Transplant*. Aug 2009;44(4):237-242. PMID 19234510
25. Aglietta M, Barkholt L, Schianca FC, et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation in metastatic colorectal cancer as a novel adoptive cell therapy approach. The European Group for Blood and Marrow Transplantation Experience. *Biol Blood Marrow Transplant*. Mar 2009;15(3):326-335. PMID 19203723
26. Kanda Y, Omuro Y, Baba E, et al. Allo-SCT using reduced-intensity conditioning against advanced pancreatic cancer: a Japanese survey. *Bone Marrow Transplant*. Jul 2008;42(2):99-103. PMID 18391987
27. Abe Y, Ito T, Baba E, et al. Nonmyeloablative allogeneic hematopoietic stem cell transplantation as immunotherapy for pancreatic cancer. *Pancreas*. Oct 2009;38(7):815-819. PMID 19696692
28. Omazic B, Ayoglu B, Lohr M, et al. A preliminary report: radical surgery and stem cell transplantation for the treatment of patients with pancreatic cancer. *J Immunother*. Mar 23 2017. PMID 28338506

29. Toh HC, Chia WK, Sun L, et al. Graft-vs.-tumor effect in patients with advanced nasopharyngeal cancer treated with nonmyeloablative allogeneic PBSC transplantation. *Bone Marrow Transplant.* Apr 2011;46(4):573-579. PMID 20661236
30. Omazic B, Remberger M, Barkholt L, et al. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for solid cancer. *Biol Blood Marrow Transplant.* Apr 2016;22(4):676-681. PMID 26740375
31. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed December 12, 2017.
32. Majhail NS, Farnia SH, Carpenter PA, et al. Indications for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation. *Biol Blood Marrow Transplant.* Nov 2015;21(11):1863-1869. PMID 26256941
33. Centers for Medicare & Medicaid Services. National Coverage Determination (NCD) for STEM CELL Transplantation (110.8.1). 2010; https://www.cms.gov/medicare-coverage-database/details/ncddetails.aspx?ncd_id=45&ncdver=5&coverageselection=both&articletype=all&policytype=final&s=pennsylvania&keyword=stem+cell&keywordlookup=title&keywordsearchtype=and&bc=gaaaabaaaaa&. Accessed December 12, 2017.